M. Florencia Iulita, PhD, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, discusses the importance of incorporating biomarkers into clinical practice for the diagnosis of Alzheimer’s disease (AD) in patients with Down syndrome, to assist in differentiating the cognitive impairment associated with AD from the intellectual disability characteristic of Down syndrome. Though there have been significant advances in the field of biomarkers using data from clinical trials, using them in a real-world setting is a crucial next step. This interview took place during the Alzheimer’s Association International Conference (AAIC), 2021.
